How to choose the maintenance treatment plan after HSCT for R/R malignanthematological patients?

How to choose the maintenance treatment plan after HSCT for R/R malignanthematological patients?

Relapse/refractory (R/R) has always been a difficult point in the clinical treatment of malignant hematological tumors. Hematopoietic stem cell transplantation (HSCT) is an important treatment for these patients to achieve long-term survival. Subsequent maintenance treatment is essential to consolidate the effects of HSCT and prevent disease recurrence. Therefore, researchers have been focusing on optimizing the specific maintenance treatment plan for a long time.
Dr. Xingyu Cao: Post-transplant maintenance therapy with Chidamide in T-ALL patients is expected to reduce relapse and improve survival

Dr. Xingyu Cao: Post-transplant maintenance therapy with Chidamide in T-ALL patients is expected to reduce relapse and improve survival

Acute T-cell lymphoblastic leukemia (T-ALL) is a highly heterogeneous malignant tumor of the hematopoietic system caused by the malignant transformation of T-cell precursors. It has significant differences from B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in clinical features, cellular genetics, molecular biology, and abnormal signal transduction pathways. T-ALL accounts for 10%-15% in children and 20%-25% in adults. Adult T-ALL has a poor prognosis due to primary chemotherapy resistance and early recurrence, with a 5-year event-free survival rate of only 20%-50%. The main challenge for T-ALL patients after transplantation is recurrence. From April 23-26, 2023, the EBMT Annual Meeting was grandly held in Paris, France. At the meeting, Dr. Cao Xingyu from Hebei Yanda Ludao Pei Hospital reported a clinical study (abstract number: 351), which suggested that the use of Chidamide for maintenance treatment might improve the survival of T-ALL patients after allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

The 49th European Bone Marrow Transplantation Annual Meeting (EBMT 2023) took place in Paris, France, from April 23 to 26, 2023. Experts and scholars from various countries gathered to present exciting advancements in research. In the field of blood tests, the fifty-year anniversary of flow cytometry coincided with this year's conference. Over the past half-century, this technology has become an indispensable tool in the diagnosis and follow-up of hematological malignancies. Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults, and the detection of Minimal Residual Disease (MRD) plays a crucial role in clinical treatment and prognosis assessment, despite encountering various technical challenges. With the release of two significant expert consensus statements by the European Leukemia Network (ELN) in 2018 and 2021, technical issues related to AML MRD detection by Multiparameter Flow Cytometry (MFC) were discussed, making this research once again the focus of the hematology field.
Dr. Min Xiong: Incorporating Cytarabine in the Pre-treatment for Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemia with Extramedullary Disease is Safe and Effective

Dr. Min Xiong: Incorporating Cytarabine in the Pre-treatment for Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemia with Extramedullary Disease is Safe and Effective

Allogeneic hematopoietic stem cell transplantation is among the most effective methods for treating malignant hematopoietic tumors. However, for extramedullary leukemia, even with high-intensity chemotherapy and transplantation, the recurrence rate remains high. To improve the prognosis, it's essential to optimize the pre-treatment plan and reduce recurrence.At this EBMT annual meeting,Dr. Min Xiong from Hebei Yanda Ludaopei Hospital reported a clinical study (Abstract No.: 1100). Results indicate that a pre-treatment regimen incorporating cytarabine for haploidentical hematopoietic stem cell transplantation to treat extramedullary leukemia is both safe and effective. We've invited Dr. Xiong  for a  interpretation of this research.
Dr. Huibiao Zhang: ThreeOsimertinib  Adjuvant Studies Shine at ELCC, Adding New Evidence for Early-Stage Lung Cancer Treatment

Dr. Huibiao Zhang: ThreeOsimertinib  Adjuvant Studies Shine at ELCC, Adding New Evidence for Early-Stage Lung Cancer Treatment

The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.
Dr. Zhengfei Zhu: Can EGFR-TKI Combined with Local Consolidative Therapy Achieve “1+1＞2”?

Dr. Zhengfei Zhu: Can EGFR-TKI Combined with Local Consolidative Therapy Achieve “1+1＞2”?

The 2023 European Lung Cancer Congress (ELCC) is taking place in Copenhagen, the capital of the fairy tale kingdom of Denmark. On the first day of the conference, a session of oral presentations showcased the Phase II randomized study data on EGFR-TKI combined with local consolidative therapy for treating EGFR mutant metastatic non-small cell lung cancer (NSCLC) . Dr.  Zhengfei Zhu from Fudan University Affiliated Tumor Hospital provides commentary on these research findings.
The urology team of West China Hospital has selected multiple studies for the 2023 EAU conference

The urology team of West China Hospital has selected multiple studies for the 2023 EAU conference

The 38th European Association of Urology (EAU23) Annual Meeting took place from March 10th to 13th, 2023, in Milan, Italy, the fashion capital of the world. The EAU Annual Meeting is one of the most closely watched urological conferences in Europe and even globally, attracting over 15,000 urology experts from around the world each year. At this conference, West China Hospital of Sichuan University reported Several studies.
Two Studies of Dr. Yong Xu’s Teamat the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

Two Studies of Dr. Yong Xu’s Teamat the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

The 38th Annual Congress of the European Association of Urology (EAU23) took place in Milan, Italy, from March 10 to 13, 2023. EAU Congress is one of the most highly anticipated urology conferences in Europe and worldwide, attracting over 15,000 urology experts from around the globe each year. At this year's EAU Congress, Dr. Yong Xu's team from the Second Hospital of Tianjin Medical University had two related studies on prostate cancer selected for presentation, exploring radical excision surgery without biopsies for highly suspicious prostate cancer patients and comparing regional saturation biopsies to targeted biopsies for initial evaluation of suspected prostate cancer patients. These research findings offer new perspectives on prostate cancer biopsies and non-invasive diagnostics.
Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023

Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023

The 28th European Hematology Association (EHA) meeting was held in Frankfurt, Germany from June 8 to June 11, 2023, adopting a hybrid online and offline conference format. As the largest international conference in the European hematology field, the EHA meeting shares topics in various scientific, clinical, and fundamental researches, covering both benign and malignant hematology and discussing the latest advances in hematology. In the treatment of acute lymphoblastic leukemia (ALL), there was significant progress made at this EHA meeting, mainly focused on immunotherapy. To further grasp the content in this area, Oncology Frontier interviewed Professor Ma Jun from the Harbin Institute of Hematology & Oncology and discussed this topic in detail.
Two renal cancer-related studies by Dr. KanGong ‘s team selected for the 2023 EAU Annual Meeting

Two renal cancer-related studies by Dr. KanGong ‘s team selected for the 2023 EAU Annual Meeting

The 38th European Association of Urology Annual Meeting (EAU23) was held in Milan, Italy, the world's fashion capital, from March 10 to 13, 2023. The EAU annual conference is one of the most closely watched urology conferences in Europe and even globally, attracting over 15,000 urology experts worldwide every year. At this EAU conference, two kidney cancer-related studies from the team of Dr  Kan Gong of Peking University First Hospital were selected for discussion. The research indicates that the age of first onset is an independent risk factor affecting the prognosis in patients with large fragment deletions of Von Hippel-Lindau (VHL) syndrome. These patients may benefit from tyrosine kinase inhibitor (TKI) treatment. Initial CD4+T cells and memory CD4+T cells may be specific immune cells infiltrating VHL syndrome-related kidney cancer, and their infiltration level is closely related to VHL protein expression and patient prognosis.